The early-stage medical device company, MicroOptx, is on a mission to change the way the world treats glaucoma by leveraging academic bioengineering, surgical expertise, microengineering manufacturing, and nanotechnology. Its platform technology shunts aqueous humor from the anterior chamber to the surface of the eye, allowing doctors to lower intraocular pressure that would otherwise lead to blindness. Led by recognized medical, industry, and financial veterans, the company's devices have a clear regulatory pathway and offer a modern solution to the vexing problem of glaucoma.